We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Amends Bristol-Myers Squibb’s Daklinza Breakthrough Therapy
FDA Amends Bristol-Myers Squibb’s Daklinza Breakthrough Therapy
The FDA has revised Bristol-Myers Squibb’s breakthrough therapy designation for its daclatasvir/sofosbuvir combination hepatitis C therapy to cover patients with advanced cirrhosis or whose infection recurs after a liver transplant.